Strategies for designing proteolysis targeting chimaeras (PROTACs)
The DOI matches its Crossref record; 103 of the 103 references it cites were found in a registry or an index.
Abstract
Proteolysis targeting chimaeras (PROTACs) is a cutting edge and rapidly growing technique for new drug discovery and development. Currently, the largest challenge in the molecular design and drug development of PROTACs is efficient identification of potent and drug‐like degraders. This review aims to comprehensively summarize and analyse state‐of‐the‐art methods and strategies in the design of PROTACs. We provide a detailed illustration of the general principles and tactics for designing potent PROTACs, highlight representative case studies, and discuss the advantages and limitations of these strategies. Particularly, structure‐based rational PROTAC design and emerging new types of PROTACs (e.g., homo‐PROTACs, multitargeting PROTACs, photo‐control PROTACs and PROTAC‐based conjugates) will be focused on.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
In Vivo Activation of the p53 Pathway by Small-Molecule Antagonists of MDM2
Vassilev, L. T., Vu, B. T., Graves, B., Carvajal, D., Podlaski, F., Filipovic, Z., Kong, N., Kammlott, U., Lukacs, C., Klein, C., et al. (2004) · Science · doi:10.1126/science.1092472 · Cited by 4,661 · cited 1×
“Nutlins represent an important class of MDM2‐binding ligands.(160) Nutlin‐3 and”
BackgroundTranscriptional silencing and longevity protein Sir2 is an NAD-dependent histone deacetylase
Imai, S.-I., Armstrong, C. M., Kaeberlein, M., & Guarente, L. (2000) · Nature · doi:10.1038/35001622 · Cited by 3,510 · cited 1×
“Sirt 2 is a member of NAD‐dependent class III lysine deacetylase family, which is involved in a variety of cellular processes, including signaling transcription, metabolic pathways, senescence, and inflammation.(194) In 2018, HE ET AL.”
BackgroundMomand, J., Zambetti, G. P., Olson, D. C., George, D., & Levine, A. J. (1992) · Cell · doi:10.1016/0092-8674(92)90644-r · Cited by 3,113 · cited 1×
“MDM2 has dual functions as both an antitumor target and an E3 ligase.(229,230) Our group designed the first MDM2‐ based homo‐PROTACs by linking two molecules of the MDM2 inhibitor Nutlin‐3.”
BackgroundProtein Misfolding, Amyloid Formation, and Human Disease: A Summary of Progress Over the Last Decade
Chiti, F., & Dobson, C. M. (2017) · Annual Review of Biochemistry · doi:10.1146/annurev-biochem-061516-045115 · Cited by 2,629 · cited 1×
“aggregates causes cell toxicity and appears to trigger or exacerbate a wide range of human diseases, including malignancies, inflammation and neurodegenerative diseases and cardiovascular disorders.(4,5) Therefore, the removal of these abnormal proteins is essential for protein homeostasis and cell survival.”
BackgroundSakamoto, K. M., Kim, K. B., Kumagai, A., Mercurio, F., Crews, C. M., & Deshaies, R. J. (2001) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.141230798 · Cited by 2,609 · cited 1×
“in 2001(18); the PROTAC molecule generated by this group employed a β‐TRCP E3‐recruiting peptide as the E3 ligase ligand to induce MetAP‐2 degradation.(18) The first complete small‐molecule PROTAC was developed utilizing nutlin to recruit the E3 ligase murine double minute 2 (MDM2) to induce androgen receptor (AR) deg…”
MethodAdapting Proteostasis for Disease Intervention
Balch, W. E., Morimoto, R. I., Dillin, A., & Kelly, J. W. (2008) · Science · doi:10.1126/science.1141448 · Cited by 2,495 · cited 1×
“One of the essential regulatory mechanisms in living cells involves the homeostasis maintained between protein biosynthesis and degradation.(3) The accumulation of misfolded proteins or”
BackgroundA Comprehensive Survey of Ras Mutations in Cancer
Prior, I. A., Lewis, P. D., & Mattos, C. (2012) · Cancer Research · doi:10.1158/0008-5472.can-11-2612 · Cited by 2,063 · cited 1×
“Mutational activation of KRAS is a common feature accounting for approximately 20% of human cancers.(208) G12C‐”
BackgroundRAS Proteins and Their Regulators in Human Disease
Simanshu, D. K., Nissley, D. V., & McCormick, F. (2017) · Cell · doi:10.1016/j.cell.2017.06.009 · Cited by 1,943
Lenalidomide Causes Selective Degradation of IKZF1 and IKZF3 in Multiple Myeloma Cells
Krönke, J., Udeshi, N. D., Narla, A., Grauman, P., Hurst, S. N., McConkey, M., Svinkina, T., Heckl, D., Comer, E., Li, X., et al. (2014) · Science · doi:10.1126/science.1244851 · Cited by 1,879 · cited 2×
“Pomalidomide exerted antitumour effects by degrading IKZF1/3 via the CRBN E3 ligase.(132,133) The activity of pomalidomide mainly depends on the key HB interactions between the glutarimide NH group and the backbone carbonyl of His380 in CRBN, which are blocked after the introduction of the NVOC group.”
BackgroundThe p53-mdm-2 autoregulatory feedback loop.
Wu, X., Bayle, J. H., Olson, D., & Levine, A. J. (1993) · Genes & Development · doi:10.1101/gad.7.7a.1126 · Cited by 1,801
Androgen Receptor in Prostate Cancer
Heinlein, C. A., & Chang, C. (2004) · Endocrine Reviews · doi:10.1210/er.2002-0032 · Cited by 1,780
Kulak, N. A., Pichler, G., Paron, I., Nagaraj, N., & Mann, M. (2014) · Nature Methods · doi:10.1038/nmeth.2834 · Cited by 1,719 · cited 1×
“There are more than 10,000 different kinds of proteins with approximately three billion individual protein molecules in a human cell.(1,2) This striking complexity of the entire proteome requires precise and tight regulation on multiple”
BackgroundThe Myeloma Drug Lenalidomide Promotes the Cereblon-Dependent Destruction of Ikaros Proteins
Lu, G., Middleton, R. E., Sun, H., Naniong, M., Ott, C. J., Mitsiades, C. S., Wong, K.-K., Bradner, J. E., & Kaelin, W. G. (2014) · Science · doi:10.1126/science.1244917 · Cited by 1,583
Histone deacetylases and their inhibitors in cancer, neurological diseases and immune disorders
Falkenberg, K. J., & Johnstone, R. W. (2014) · Nature Reviews Drug Discovery · doi:10.1038/nrd4360 · Cited by 1,564 · cited 1×
“HDAC plays an important role in regulating chromatin structure, transcription factors, and nonhistone functions.(188) Five HDAC inhibitors have been approved as therapeutic antitumor agents.”
BackgroundCatalytic in vivo protein knockdown by small-molecule PROTACs
Bondeson, D. P., Mares, A., Smith, I. E. D., Ko, E., Campos, S., Miah, A. H., Mulholland, K. E., Routly, N., Buckley, D. L., Gustafson, J. L., et al. (2015) · Nature Chemical Biology · doi:10.1038/nchembio.1858 · Cited by 1,356
Resistance Mechanisms for the Bruton's Tyrosine Kinase Inhibitor Ibrutinib
Woyach, J. A., Furman, R. R., Liu, T.-M., Ozer, H. G., Zapatka, M., Ruppert, A. S., Xue, L., Li, D. H.-H., Steggerda, S. M., Versele, M., et al. (2014) · New England Journal of Medicine · doi:10.1056/nejmoa1400029 · Cited by 1,275
Structural basis of PROTAC cooperative recognition for selective protein degradation
Gadd, M. S., Testa, A., Lucas, X., Chan, K.-H., Chen, W., Lamont, D. J., Zengerle, M., & Ciulli, A. (2017) · Nature Chemical Biology · doi:10.1038/nchembio.2329 · Cited by 1,242
Lysosome-targeting chimaeras for degradation of extracellular proteins
Banik, S. M., Pedram, K., Wisnovsky, S., Ahn, G., Riley, N. M., & Bertozzi, C. R. (2020) · Nature · doi:10.1038/s41586-020-2545-9 · Cited by 1,199
Structure of the DDB1–CRBN E3 ubiquitin ligase in complex with thalidomide
Fischer, E. S., Böhm, K., Lydeard, J. R., Yang, H., Stadler, M. B., Cavadini, S., Nagel, J., Serluca, F., Acker, V., Lingaraju, G. M., et al. (2014) · Nature · doi:10.1038/nature13527 · Cited by 1,141
Hijacking the E3 Ubiquitin Ligase Cereblon to Efficiently Target BRD4
Lu, J., Qian, Y., Altieri, M., Dong, H., Wang, J., Raina, K., Hines, J., Winkler, J. D., Crew, A. P., Coleman, K., et al. (2015) · Chemistry & Biology · doi:10.1016/j.chembiol.2015.05.009 · Cited by 1,140
The dTAG system for immediate and target-specific protein degradation
Nabet, B., Roberts, J. M., Buckley, D. L., Paulk, J., Dastjerdi, S., Yang, A., Leggett, A. L., Erb, M. A., Lawlor, M. A., Souza, A., et al. (2018) · Nature Chemical Biology · doi:10.1038/s41589-018-0021-8 · Cited by 1,118 · cited 2×
“FKBP12 is closely related to heart development and plays a crucial role in regulating the differentiation of heart cells and the initiation of a heartbeat.214 In 2018, Bradner et al. designed a series of PROTACs targeting FKBP12 based on a CRBN ligand and FKBP12F36V selective inhibitor AP1867.”
BackgroundProteolysis-Targeting Chimeras as Therapeutics and Tools for Biological Discovery
Burslem, G. M., & Crews, C. M. (2020) · Cell · doi:10.1016/j.cell.2019.11.031 · Cited by 1,079 · cited 1×
“Currently, the largest challenge in the molecular design and drug development of PROTACs is efficient identification drug‐like candidates.(257) The PROTAC discovery process remains empirical and largely depends on substantial efforts in synthetic and medicinal chemistry, which are time‐consuming and expensive.”
BackgroundSelective Small Molecule Induced Degradation of the BET Bromodomain Protein BRD4
Zengerle, M., Chan, K.-H., & Ciulli, A. (2015) · ACS Chemical Biology · doi:10.1021/acschembio.5b00216 · Cited by 1,056 · cited 1×
“developed PROTAC 44 by extending the linker of compound 49.(116) After treatment with PROTAC 44 at 1 nM,”
MethodProgrammed Anuclear Cell Death Delimits Platelet Life Span
Mason, K. D., Carpinelli, M. R., Fletcher, J. I., Collinge, J. E., Hilton, A. A., Ellis, S., Kelly, P. N., Ekert, P. G., Metcalf, D., Roberts, A. W., et al. (2007) · Cell · doi:10.1016/j.cell.2007.01.037 · Cited by 1,031 · cited 1×
“However, the effectiveness of Bcl‐XL inhibitors is generally limited by toxicity to platelets.(123) On the basis of the Bcl‐XL inhibitor ABT263, Khan et al.”
BackgroundLessons in PROTAC Design from Selective Degradation with a Promiscuous Warhead
Bondeson, D. P., Smith, B. E., Burslem, G. M., Buhimschi, A. D., Hines, J., Jaime-Figueroa, S., Wang, J., Hamman, B. D., Ishchenko, A., & Crews, C. M. (2018) · Cell Chemical Biology · doi:10.1016/j.chembiol.2017.09.010 · Cited by 923 · cited 1×
“However, E3 ligases exhibit unique and limited substrate specificity.(220) Thus, the design of PROTACs with covalent E3 ligase ligands is an alternative way to improve the potency and selectivity of PROTACs and to discover new E3 ligases suitable for PROTAC design (Figure 19).”
BackgroundPROTAC-induced BET protein degradation as a therapy for castration-resistant prostate cancer
Raina, K., Lu, J., Qian, Y., Altieri, M., Gordon, D., Rossi, A. M. K., Wang, J., Chen, X., Dong, H., Siu, K., et al. (2016) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1521738113 · Cited by 852 · cited 4×
“ARV‐771 (49), designed by connecting the BET inhibitor JQ1 to a VHL ligand, effectively enhance the antiproliferative efficacy of castration‐resistant prostate cancer (CRPC) cells compared with the BET inhibitor OTX015.”
BackgroundInfluentialAnticancer sulfonamides target splicing by inducing RBM39 degradation via recruitment to DCAF15
Han, T., Goralski, M., Gaskill, N., Capota, E., Kim, J., Ting, T. C., Xie, Y., Williams, N. S., & Nijhawan, D. (2017) · Science · doi:10.1126/science.aal3755 · Cited by 762
A selective BCL-XL PROTAC degrader achieves safe and potent antitumor activity
Khan, S., Zhang, X., Lv, D., Zhang, Q., He, Y., Zhang, P., Liu, X., Thummuri, D., Yuan, Y., Wiegand, J. S., et al. (2019) · Nature Medicine · doi:10.1038/s41591-019-0668-z · Cited by 688
AUTACs: Cargo-Specific Degraders Using Selective Autophagy
Takahashi, D., Moriyama, J., Nakamura, T., Miki, E., Takahashi, E., Sato, A., Akaike, T., Itto-Nakama, K., & Arimoto, H. (2019) · Molecular Cell · doi:10.1016/j.molcel.2019.09.009 · Cited by 675
Schneekloth, A. R., Pucheault, M., Tae, H. S., & Crews, C. M. (2008) · Bioorganic & Medicinal Chemistry Letters · doi:10.1016/j.bmcl.2008.07.114 · Cited by 635
Modular PROTAC design for the degradation of oncogenic BCR-ABL
Lai, A. C., Toure, M., Hellerschmied, D., Salami, J., Jaime‐Figueroa, S., Ko, E., Hines, J., & Crews, C. M. (2016) · Angewandte Chemie International Edition · doi:10.1002/anie.201507634 · Cited by 618
Plasticity in binding confers selectivity in ligand-induced protein degradation
Nowak, R. P., DeAngelo, S. L., Buckley, D., He, Z., Donovan, K. A., An, J., Safaee, N., Jedrychowski, M. P., Ponthier, C. M., Ishoey, M., et al. (2018) · Nature Chemical Biology · doi:10.1038/s41589-018-0055-y · Cited by 615
Buckley, D. L., Van Molle, I., Gareiss, P. C., Tae, H. S., Michel, J., Noblin, D. J., Jorgensen, W. L., Ciulli, A., & Crews, C. M. (2012) · Journal of the American Chemical Society · doi:10.1021/ja209924v · Cited by 569 · cited 1×
“Furthermore, virtual screening and structural optimization revealed that nanomolar concentrations of VHL small‐molecule inhibitors (15 and 16) showed improved membrane permeability, which facilitated the design of small‐molecule degraders.(113) 1298 | HE ET AL.”
BackgroundBAF complex vulnerabilities in cancer demonstrated via structure-based PROTAC design
Farnaby, W., Koegl, M., Roy, M. J., Whitworth, C., Diers, E., Trainor, N., Zollman, D., Steurer, S., Karolyi-Oezguer, J., Riedmueller, C., et al. (2019) · Nature Chemical Biology · doi:10.1038/s41589-019-0294-6 · Cited by 562
Pharmacological perturbation of CDK9 using selective CDK9 inhibition or degradation
Olson, C. M., Jiang, B., Erb, M. A., Liang, Y., Doctor, Z. M., Zhang, Z., Zhang, T., Kwiatkowski, N., Boukhali, M., Green, J. L., et al. (2018) · Nature Chemical Biology · doi:10.1038/nchembio.2538 · Cited by 552 · cited 1×
“However, in some cases, selective POI ligands may not yield selective degraders.(168) In addition, reasonable adjustment of the linker length in PROTACs has an important effect on the selectivity towards homologous proteins.”
BackgroundBlazek, D., Kohoutek, J., Bartholomeeusen, K., Johansen, E., Hulinkova, P., Luo, Z., Cimermancic, P., Ule, J., & Peterlin, B. M. (2011) · Genes & Development · doi:10.1101/gad.16962311 · Cited by 522 · cited 1×
“CDK12, an important member of CDKs, plays a key role in regulating the transcription of genes that respond to DNA damage.(186) However, the understanding of biological function of CDK12 is hampered by its homologous”
BackgroundDifferential PROTAC substrate specificity dictated by orientation of recruited E3 ligase
Smith, B. E., Wang, S. L., Jaime-Figueroa, S., Harbin, A., Wang, J., Hamman, B. D., & Crews, C. M. (2019) · Nature Communications · doi:10.1038/s41467-018-08027-7 · Cited by 517 · cited 1×
“clinical drugs, drug candidates in clinical trials or highly active inhibitors are always favourable for PROTAC design due to their optimized pharmacokinetic (PK) and PK/pharmacodynamic (PD) properties.(43) Information on the binding modes of ligand candidates contributes to rational PROTAC design.”
BackgroundProtac-Induced Protein Degradation in Drug Discovery: Breaking the Rules or Just Making New Ones?
Churcher, I. (2018) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.7b01272 · Cited by 491
Development of targeted protein degradation therapeutics
Chamberlain, P. P., & Hamann, L. G. (2019) · Nature Chemical Biology · doi:10.1038/s41589-019-0362-y · Cited by 489 · cited 1×
“number of PROTACs that degrade diverse targets for the treatment of various diseases have been discovered.(20) To date, more than 10 PROTACs have been entered into clinical trials.”
BackgroundElectrophilic PROTACs that degrade nuclear proteins by engaging DCAF16
Zhang, X., Crowley, V. M., Wucherpfennig, T. G., Dix, M. M., & Cravatt, B. F. (2019) · Nature Chemical Biology · doi:10.1038/s41589-019-0279-5 · Cited by 487 · cited 1×
“The Cravatt group designed covalent PROTACs by integrating electrophilic small‐molecule ligands that covalently bound with specific cysteine residues in E3 ligases to induce the degradation of target proteins.(221)”
BackgroundTargeted Degradation of Oncogenic KRAS G12C by VHL-Recruiting PROTACs
Bond, M. J., Chu, L., Nalawansha, D. A., Li, K., & Crews, C. M. (2020) · ACS Central Science · doi:10.1021/acscentsci.0c00411 · Cited by 450
Harnessing the anti-cancer natural product nimbolide for targeted protein degradation
Spradlin, J. N., Hu, X., Ward, C. C., Brittain, S. M., Jones, M. D., Ou, L., To, M., Proudfoot, A., Ornelas, E., Woldegiorgis, M., et al. (2019) · Nature Chemical Biology · doi:10.1038/s41589-019-0304-8 · Cited by 432 · cited 1×
“To clarify the mechanism of action of nimbolide, Nomura's group performed proteomic screening and found that nimbolide bound to the C8 site of RNF114, which is a member of the RING family of E3 ubiquitin ligases and mediates the ubiquitination of p21, p57, and other proteins.(64) Furthermore,”
BackgroundSmall-molecule hydrophobic tagging–induced degradation of HaloTag fusion proteins
Neklesa, T. K., Tae, H. S., Schneekloth, A. R., Stulberg, M. J., Corson, T. W., Sundberg, T. B., Raina, K., Holley, S. A., & Crews, C. M. (2011) · Nature Chemical Biology · doi:10.1038/nchembio.597 · Cited by 429
Edmondson, S. D., Yang, B., & Fallan, C. (2019) · Bioorganic & Medicinal Chemistry Letters · doi:10.1016/j.bmcl.2019.04.030 · Cited by 422
Delineating the role of cooperativity in the design of potent PROTACs for BTK
Zorba, A., Nguyen, C., Xu, Y., Starr, J., Borzilleri, K., Smith, J., Zhu, H., Farley, K. A., Ding, W., Schiemer, J., et al. (2018) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1803662115 · Cited by 419
Protein Degradation by In-Cell Self-Assembly of Proteolysis Targeting Chimeras
Lebraud, H., Wright, D. J., Johnson, C. N., & Heightman, T. D. (2016) · ACS Central Science · doi:10.1021/acscentsci.6b00280 · Cited by 413 · cited 2×
“A pioneering strategy called in‐cell click‐formed proteolysis targeting chimaeras (CLIPTACs) has been developed to address the limitations of the large MW and poor cell permeability of conventional PROTACs.(86) Trans‐cyclooctene and tetrazine precursor molecules in cells are capable of self‐assembly based on biorthogo…”
BackgroundMethodTargeted protein degraders crowd into the clinic
Mullard, A. (2021) · Nature Reviews Drug Discovery · doi:10.1038/d41573-021-00052-4 · Cited by 409
Itoh, Y., Ishikawa, M., Naito, M., & Hashimoto, Y. (2010) · Journal of the American Chemical Society · doi:10.1021/ja100691p · Cited by 404 · cited 1×
“In 2010, the Hashimoto group developed a PROTAC (74, Figure 14) consisting of MeBS and all‐trans‐ retinoic acid (ATRA).(154) The MeBS part selectively binds to the BIR3 domain of CIAP1, while the ATRA part binds to intracellular retinoic acid‐binding proteins (CRABP‐1 and CRABP‐2).”
MethodHDAC6, at the crossroads between cytoskeleton and cell signaling by acetylation and ubiquitination
Boyault, C., Sadoul, K., Pabion, M., & Khochbin, S. (2007) · Oncogene · doi:10.1038/sj.onc.1210614 · Cited by 397 · cited 1×
“HDAC6 belongs to the HDAC IIb family, which is closely related to a variety of diseases.(190) In 2018, Yang et al.”
BackgroundSelective degradation of splicing factor CAPERα by anticancer sulfonamides
Uehara, T., Minoshima, Y., Sagane, K., Sugi, N. H., Mitsuhashi, K. O., Yamamoto, N., Kamiyama, H., Takahashi, K., Kotake, Y., Uesugi, M., et al. (2017) · Nature Chemical Biology · doi:10.1038/nchembio.2363 · Cited by 396 · cited 2×
“In 2017, the Uehara and Ting groups reported that coactivator of activating protein‐1 and estrogen receptor α (CAPERα) was degraded through the proteasome pathway in conjunction with the formation of a complex consisting of CAPERα, sulfonamide, DDB1‐ and CUL4‐associated factor 15 (DCAF15), DDB1 and CUL4.”
BackgroundBuhimschi, A. D., Armstrong, H. A., Toure, M., Jaime-Figueroa, S., Chen, T. L., Lehman, A. M., Woyach, J. A., Johnson, A. J., Byrd, J. C., & Crews, C. M. (2018) · Biochemistry · doi:10.1021/acs.biochem.8b00391 · Cited by 394
Covalent inhibitors: a rational approach to drug discovery
Sutanto, F., Konstantinidou, M., & Dömling, A. (2020) · RSC Medicinal Chemistry · doi:10.1039/d0md00154f · Cited by 389
Light-Induced Protein Degradation with Photocaged PROTACs
Xue, G., Wang, K., Zhou, D., Zhong, H., & Pan, Z. (2019) · Journal of the American Chemical Society · doi:10.1021/jacs.9b06422 · Cited by 377 · cited 4×
“Pan et al. developed an alternative strategy to prevent the formation of ternary complexes by hampering the binding between PC‐PROTAC and its POI.241 They designed PC‐PROTAC 132 by attaching the DMNB group to the amide nitrogen of the BRD4 inhibitor JQ1 (Figure 25).”
MethodInfluentialMolecular Glues for Targeted Protein Degradation: From Serendipity to Rational Discovery
Dong, G., Ding, Y., He, S., & Sheng, C. (2021) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.1c00895 · Cited by 369
Self-citationAn, S., & Fu, L. (2018) · EBioMedicine · doi:10.1016/j.ebiom.2018.09.005 · Cited by 363
Mapping the Degradable Kinome Provides a Resource for Expedited Degrader Development
Donovan, K. A., Ferguson, F. M., Bushman, J. W., Eleuteri, N. A., Bhunia, D., Ryu, S., Tan, L., Shi, K., Yue, H., Liu, X., et al. (2020) · Cell · doi:10.1016/j.cell.2020.10.038 · Cited by 359
Antibody–PROTAC Conjugates Enable HER2-Dependent Targeted Protein Degradation of BRD4
Maneiro, M., Forte, N., Shchepinova, M. M., Kounde, C. S., Chudasama, V., Baker, J. R., & Tate, E. W. (2020) · ACS Chemical Biology · doi:10.1021/acschembio.0c00285 · Cited by 350 · cited 2×
“designed a trastuzumab‐BRD4‐PROTAC conjugate by linking the BRD4‐targeting PROTAC MZ1 to the antibody trastuzumab with a cleavable disulfide linkage.(245) Trastuzumab selectively recognized HER2‐positive breast cancer cell lines, and the active form of this PROTAC was released after hydrolysation by lysosomes.”
BackgroundMethodSalami, J., Alabi, S., Willard, R. R., Vitale, N. J., Wang, J., Dong, H., Jin, M., McDonnell, D. P., Crew, A. P., Neklesa, T. K., et al. (2018) · Communications Biology · doi:10.1038/s42003-018-0105-8 · Cited by 349
Hines, J., Lartigue, S., Dong, H., Qian, Y., & Crews, C. M. (2019) · Cancer Research · doi:10.1158/0008-5472.can-18-2918 · Cited by 348
Zoppi, V., Hughes, S. J., Maniaci, C., Testa, A., Gmaschitz, T., Wieshofer, C., Koegl, M., Riching, K. M., Daniels, D. L., Spallarossa, A., et al. (2019) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.8b01413 · Cited by 336 · cited 3×
“In 2019, Zoppi designed PROTAC VZ185 (98) by combining a VHL ligand and BRD9 inhibitors.(166) Compound 98 effectively degraded BRD9 and BRD7 with DC50 values of 1.”
BackgroundWard, C. C., Kleinman, J. I., Brittain, S. M., Lee, P. S., Chung, C. Y. S., Kim, K., Petri, Y., Thomas, J. R., Tallarico, J. A., McKenna, J. M., et al. (2019) · ACS Chemical Biology · doi:10.1021/acschembio.8b01083 · Cited by 336
Li, Y., Yang, J., Aguilar, A., McEachern, D., Przybranowski, S., Liu, L., Yang, C.-Y., Wang, M., Han, X., & Wang, S. (2019) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.8b00909 · Cited by 312
Lu, M., Liu, T., Jiao, Q., Ji, J., Tao, M., Liu, Y., You, Q., & Jiang, Z. (2018) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2018.01.063 · Cited by 310
Sun, Y., Zhao, X., Ding, N., Gao, H., Wu, Y., Yang, Y., Zhao, M., Hwang, J., Song, Y., Liu, W., et al. (2018) · Cell Research · doi:10.1038/s41422-018-0055-1 · Cited by 295 · cited 6×
“In 2018, Rao et al. reported the first BTK degrader P13I (106) that can prevent the development of resistance in cells expressing BTK.212 Ibrutinib and spebrutinib were selected as BTK‐binding partners, and they were conjugated to a CRBN ligand or MDM2 ligand by linkers of various lengths to obtain BTK‐targeting PROTA…”
MethodInfluentialSelf-citationAddressing Kinase-Independent Functions of Fak via PROTAC-Mediated Degradation
Cromm, P. M., Samarasinghe, K. T. G., Hines, J., & Crews, C. M. (2018) · Journal of the American Chemical Society · doi:10.1021/jacs.8b08008 · Cited by 293 · cited 2×
“At concentrations ranging from 10 to 40 nM, an initially developed FAK‐targeting PROTAC degraded only one‐half of the FAK proteins to which it was exposed.(83) After introducing the triazole group, the half‐maximal degradation rate (DC50) of compound 43 was improved: 30 pM.”
BackgroundMethodQin, C., Hu, Y., Zhou, B., Fernandez-Salas, E., Yang, C.-Y., Liu, L., McEachern, D., Przybranowski, S., Wang, M., Stuckey, J., et al. (2018) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.8b00506 · Cited by 281 · cited 1×
“At picomolar concentrations, compound 67 effectively induced the degradation of BET proteins and inhibited the proliferation of human acute leukemia cells.(137) In addition, compound 67 showed excellent in vivo antitumor potency and achieved complete and long‐lasting tumor regression in a xenograft model of human leuk…”
BackgroundExploring Targeted Degradation Strategy for Oncogenic KRASG12C
Zeng, M., Xiong, Y., Safaee, N., Nowak, R. P., Donovan, K. A., Yuan, C. J., Nabet, B., Gero, T. W., Feru, F., Li, L., et al. (2020) · Cell Chemical Biology · doi:10.1016/j.chembiol.2019.12.006 · Cited by 275
TF-PROTACs Enable Targeted Degradation of Transcription Factors
Liu, J., Chen, H., Kaniskan, H. Ü., Xie, L., Chen, X., Jin, J., & Wei, W. (2021) · Journal of the American Chemical Society · doi:10.1021/jacs.1c03852 · Cited by 247 · cited 3×
“Recently, Wei's group developed a platform termed a TF‐PROTAC (TF‐PROTAC), which is able to induce selective degradation of TFs based on specific recognition/binding of DNA oligomers by TFs (Figure 7B).(87) An azide‐modified TF‐specific DNA oligonucleotide was linked with a bicyclooctyne‐modified E3 ligase ligand via…”
MethodInfluentialManiaci, C., Hughes, S. J., Testa, A., Chen, W., Lamont, D. J., Rocha, S., Alessi, D. R., Romeo, R., & Ciulli, A. (2017) · Nature Communications · doi:10.1038/s41467-017-00954-1 · Cited by 245 · cited 1×
“complex with its specific ligands; in this case, two identical ligands were connected with linkers of different lengths.(227) The best compound, CM11 (120), completely degraded pVHL at a concentration of 10 nM.”
BackgroundOhoka, N., Okuhira, K., Ito, M., Nagai, K., Shibata, N., Hattori, T., Ujikawa, O., Shimokawa, K., Sano, O., Koyama, R., et al. (2017) · Journal of Biological Chemistry · doi:10.1074/jbc.m116.768853 · Cited by 240 · cited 2×
“, LCL161 derivatives 21–22).(156) A series of PROTACs with LCL161 derivatives as E3 ligase”
BackgroundProteolysis Targeting Chimeras (PROTACs) of Anaplastic Lymphoma Kinase (ALK)
Zhang, C., Han, X.-R., Yang, X., Jiang, B., Liu, J., Xiong, Y., & Jin, J. (2018) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2018.03.071 · Cited by 226 · cited 1×
“The activity of pomalidomide mainly depends on the key HB interactions between the glutarimide NH group and the backbone carbonyl of His380 in CRBN, which are blocked after the introduction of the NVOC group.(136,268,269) Thus, caged PC‐poma-”
BackgroundPRosettaC: Rosetta Based Modeling of PROTAC Mediated Ternary Complexes
Zaidman, D., Prilusky, J., & London, N. (2020) · Journal of Chemical Information and Modeling · doi:10.1021/acs.jcim.0c00589 · Cited by 224
Functional TRIM24 degrader via conjugation of ineffectual bromodomain and VHL ligands
Gechijian, L. N., Buckley, D. L., Lawlor, M. A., Reyes, J. M., Paulk, J., Ott, C. J., Winter, G. E., Erb, M. A., Scott, T. G., Xu, M., et al. (2018) · Nature Chemical Biology · doi:10.1038/s41589-018-0010-y · Cited by 222 · cited 1×
“In 2018, the Bradner group designed TRIM24‐targeting PROTACs (dTRIM24, 99) by conjugating a CRBN ligand with the selective inhibitor of theTRIM24 bromodomain.(200) Compound 99 selectively induced degradation of TRIM24 with a DC50 value of 2–5 μM and Dmax value of 70%.”
MethodPROTAC-DB: an online database of PROTACs
Weng, G., Shen, C., Cao, D., Gao, J., Dong, X., He, Q., Yang, B., Li, D., Wu, J., & Hou, T. (2021) · Nucleic Acids Research · doi:10.1093/nar/gkaa807 · Cited by 219
Structural complementarity facilitates E7820-mediated degradation of RBM39 by DCAF15
Faust, T. B., Yoon, H., Nowak, R. P., Donovan, K. A., Li, Z., Cai, Q., Eleuteri, N. A., Zhang, T., Gray, N. S., & Fischer, E. S. (2020) · Nature Chemical Biology · doi:10.1038/s41589-019-0378-3 · Cited by 218
Antibody Conjugation of a Chimeric BET Degrader Enables in vivo Activity
Pillow, T. H., Adhikari, P., Blake, R. A., Chen, J., Del Rosario, G., Deshmukh, G., Figueroa, I., Gascoigne, K. E., Kamath, A. V., Kaufman, S., et al. (2020) · ChemMedChem · doi:10.1002/cmdc.201900497 · Cited by 216
Efficient targeted degradation via reversible and irreversible covalent PROTACs
Gabizon, R., Shraga, A., Gehrtz, P., Livnah, E., Gurwicz, N., Avram, L., Unger, T., Albeck, S., Shulman, Z., & London, N. (2020) · doi:10.26434/chemrxiv.11494398.v1 · Cited by 213 · cited 1×
“and covalent PROTACs, providing a valuable strategy to degrade target proteins without a suitable binding ligand.(217) Using BTK as the target protein, they systematically tested the degradation activity of a series of reversible, irreversible, and noncovalent PROTACs and further investigated the effect of covalent bo…”
BackgroundDCAF11 Supports Targeted Protein Degradation by Electrophilic Proteolysis-Targeting Chimeras
Zhang, X., Luukkonen, L. M., Eissler, C. L., Crowley, V. M., Yamashita, Y., Schafroth, M. A., Kikuchi, S., Weinstein, D. S., Symons, K. T., Nordin, B. E., et al. (2021) · Journal of the American Chemical Society · doi:10.1021/jacs.1c00990 · Cited by 199 · cited 1×
“electrophilic PROTACs bearing a SLF (synthetic ligand of FKBP12) ligand to discover novel PROTACs that degrade the FKBP12 protein in 22Rv1 human prostate cancer cells by covalently engaging E3 ligases.(222) Electrophilic PROTAC 116 was shown to exert degradation activity via covalent modification of specific cysteine…”
BackgroundIn Silico Modeling of PROTAC-Mediated Ternary Complexes: Validation and Application
Drummond, M. L., & Williams, C. I. (2019) · Journal of Chemical Information and Modeling · doi:10.1021/acs.jcim.8b00872 · Cited by 199
PROTAC-Mediated Degradation of Bruton’s Tyrosine Kinase Is Inhibited by Covalent Binding
Tinworth, C. P., Lithgow, H., Dittus, L., Bassi, Z. I., Hughes, S. E., Muelbaier, M., Dai, H., Smith, I. E. D., Kerr, W. J., Burley, G. A., et al. (2019) · ACS Chemical Biology · doi:10.1021/acschembio.8b01094 · Cited by 195 · cited 1×
“By replacing the acrylamide group with propylamide (13), a reversible BTK PROTAC induced BTK degradation in a time‐dependent and concentration‐dependent manner.(53) In contrast, an irreversible PROTAC designed with α,β‐unsaturated amides failed to degrade BTK under the same conditions.”
BackgroundDevelopment of the first small molecule histone deacetylase 6 (HDAC6) degraders
Yang, K., Song, Y., Xie, H., Wu, H., Wu, Y.-T., Leisten, E. D., & Tang, W. (2018) · Bioorganic & Medicinal Chemistry Letters · doi:10.1016/j.bmcl.2018.05.057 · Cited by 190
Self-citationLuo, M., Spradlin, J. N., Boike, L., Tong, B., Brittain, S. M., McKenna, J. M., Tallarico, J. A., Schirle, M., Maimone, T. J., & Nomura, D. K. (2021) · Cell Chemical Biology · doi:10.1016/j.chembiol.2021.01.005 · Cited by 186
Du, X., Volkov, O. A., Czerwinski, R. M., Tan, H., Huerta, C., Morton, E. R., Rizzi, J. P., Wehn, P. M., Xu, R., Nijhawan, D., et al. (2019) · Structure · doi:10.1016/j.str.2019.10.005 · Cited by 181
Burslem, G. M., Song, J., Chen, X., Hines, J., & Crews, C. M. (2018) · Journal of the American Chemical Society · doi:10.1021/jacs.8b10320 · Cited by 176 · cited 1×
“In 2018, the Crews group developed novel FLT3‐targeted PROTACs (62) by combining quizartinib and a VHL E3 ligand with an optimized PEG linker.(128) Compound 62 effectively degraded the FLT3 with internal tandem duplications (FLT3‐ITD) protein in MV4‐11 and Molm‐14 cells at low nanomolar concentrations and showed bette…”
BackgroundDragovich, P. S., Pillow, T. H., Blake, R. A., Sadowsky, J. D., Adaligil, E., Adhikari, P., Chen, J., Corr, N., dela Cruz-Chuh, J., Del Rosario, G., et al. (2021) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.0c01846 · Cited by 174 · cited 5×
“developed a platform for Ab‐PROTAC generation by conjugating a BRD4 degrader to a monoclonal antibody (Figure 28).(246,247) the Monoclonal antibodies tested specifically recognize the cell surface”
BackgroundMethodInfluentialDiscovery of SHP2-D26 as a First, Potent, and Effective PROTAC Degrader of SHP2 Protein
Wang, M., Lu, J., Wang, M., Yang, C.-Y., & Wang, S. (2020) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.0c00471 · Cited by 172 · cited 1×
“1 μM in KYSE530 cells) (Figure 5B).(77)”
Drummond, M. L., Henry, A., Li, H., & Williams, C. I. (2020) · Journal of Chemical Information and Modeling · doi:10.1021/acs.jcim.0c00897 · Cited by 166
Rationalizing PROTAC-Mediated Ternary Complex Formation Using Rosetta
Bai, N., Miller, S. A., Andrianov, G. V., Yates, M., Kirubakaran, P., & Karanicolas, J. (2021) · Journal of Chemical Information and Modeling · doi:10.1021/acs.jcim.0c01451 · Cited by 157
Dragovich, P. S., Pillow, T. H., Blake, R. A., Sadowsky, J. D., Adaligil, E., Adhikari, P., Bhakta, S., Blaquiere, N., Chen, J., dela Cruz-Chuh, J., et al. (2021) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.0c01845 · Cited by 152 · cited 5×
“developed a platform for Ab‐PROTAC generation by conjugating a BRD4 degrader to a monoclonal antibody (Figure 28).(246,247) the Monoclonal antibodies tested specifically recognize the cell surface”
BackgroundMethodInfluentialDiscovery and resistance mechanism of a selective CDK12 degrader
Jiang, B., Gao, Y., Che, J., Lu, W., Kaltheuner, I. H., Dries, R., Kalocsay, M., Berberich, M. J., Jiang, J., You, I., et al. (2021) · Nature Chemical Biology · doi:10.1038/s41589-021-00765-y · Cited by 150
Discovery of Wogonin-based PROTACs against CDK9 and capable of achieving antitumor activity
Bian, J., Ren, J., Li, Y., Wang, J., Xu, X., Feng, Y., Tang, H., Wang, Y., & Li, Z. (2018) · Bioorganic Chemistry · doi:10.1016/j.bioorg.2018.08.028 · Cited by 140
DT2216—a Bcl-xL-specific degrader is highly active against Bcl-xL-dependent T cell lymphomas
He, Y., Koch, R., Budamagunta, V., Zhang, P., Zhang, X., Khan, S., Thummuri, D., Ortiz, Y. T., Zhang, X., Lv, D., et al. (2020) · Journal of Hematology & Oncology · doi:10.1186/s13045-020-00928-9 · Cited by 139
The Proteasome in Modern Drug Discovery: Second Life of a Highly Valuable Drug Target
Cromm, P. M., & Crews, C. M. (2017) · ACS Central Science · doi:10.1021/acscentsci.7b00252 · Cited by 136 · cited 1×
“In eukaryotic cells, the UPS is the predominant protein degradation system and is involved in the degradation of more than 80% of cellular proteins.(10) The UPS induces protein degradation via a multiple‐step enzymatic process involving a ubiquitin‐activating enzyme (E1), ubiquitin‐conjugating enzyme (E2), and ubiquit…”
BackgroundTargeting IRAK4 for Degradation with PROTACs
Nunes, J., McGonagle, G. A., Eden, J., Kiritharan, G., Touzet, M., Lewell, X., Emery, J., Eidam, H., Harling, J. D., & Anderson, N. A. (2019) · ACS Medicinal Chemistry Letters · doi:10.1021/acsmedchemlett.9b00219 · Cited by 134 · cited 1×
“A research group from GSK developed a novel IRAK4‐targeted PROTAC (63) based on the IRAK4 inhibitor PF‐06650833, a spiro‐piperidinyl pyrimidine linker, and a VHL ligand.(130) Compound 63 effectively”
MethodPROTAC-mediated degradation of class I histone deacetylase enzymes in corepressor complexes
Smalley, J. P., Adams, G. E., Millard, C. J., Song, Y., Norris, J. K. S., Schwabe, J. W. R., Cowley, S. M., & Hodgkinson, J. T. (2020) · Chemical Communications · doi:10.1039/d0cc01485k · Cited by 121 · cited 2×
“Hodgkinson's group developed PROTAC 95 targeting HDAC1–3 based on the HDAC1–3 selective inhibitor CI‐994.193 At a concentration of 10 μM, compound 95 degraded HDAC1–3 in a concentration‐dependent manner in the HCT116 cell line and induced 63% of these cells to undergo apoptosis.”
BackgroundInfluentialAbsorption, metabolism and excretion of [14C]pomalidomide in humans following oral administration
Hoffmann, M., Kasserra, C., Reyes, J., Schafer, P., Kosek, J., Capone, L., Parton, A., Kim-Kang, H., Surapaneni, S., & Kumar, G. (2013) · Cancer Chemotherapy and Pharmacology · doi:10.1007/s00280-012-2040-6 · Cited by 121
Phase I Trial of the Human Double Minute 2 Inhibitor MK-8242 in Patients With Advanced Solid Tumors
Wagner, A. J., Banerji, U., Mahipal, A., Somaiah, N., Hirsch, H., Fancourt, C., Johnson-Levonas, A. O., Lam, R., Meister, A. K., Russo, G., et al. (2017) · Journal of Clinical Oncology · doi:10.1200/jco.2016.70.7117 · Cited by 120
Antibody-mediated delivery of chimeric protein degraders which target estrogen receptor alpha (ERα)
Dragovich, P. S., Adhikari, P., Blake, R. A., Blaquiere, N., Chen, J., Cheng, Y.-X., den Besten, W., Han, J., Hartman, S. J., He, J., et al. (2020) · Bioorganic & Medicinal Chemistry Letters · doi:10.1016/j.bmcl.2019.126907 · Cited by 120
Plasticity in designing PROTACs for selective and potent degradation of HDAC6
Yang, H., Lv, W., He, M., Deng, H., Li, H., Wu, W., & Rao, Y. (2019) · Chemical Communications · doi:10.1039/c9cc08509b · Cited by 108 · cited 1×
“constructed a new type of HDAC6‐targeted degrader using the strategy of connecting the HDAC6‐ selective inhibitor nexturastat A with CRBN ligand.(192) These PROTACs efficiently degraded HDAC6 at nanomolar concentrations in various solid tumor cell lines and hematoma cell lines.”
MethodDe Dominici, M., Porazzi, P., Xiao, Y., Chao, A., Tang, H.-Y., Kumar, G., Fortina, P., Spinelli, O., Rambaldi, A., Peterson, L. F., et al. (2020) · Blood · doi:10.1182/blood.2019003604 · Cited by 94
Homo-PROTAC mediated suicide of MDM2 to treat non-small cell lung cancer
He, S., Ma, J., Fang, Y., Liu, Y., Wu, S., Dong, G., Wang, W., & Sheng, C. (2021) · Acta Pharmaceutica Sinica B · doi:10.1016/j.apsb.2020.11.022 · Cited by 91
Self-citationActivation of p53 by the MDM2 inhibitor RG7112 impairs thrombopoiesis
Iancu-Rubin, C., Mosoyan, G., Glenn, K., Gordon, R. E., Nichols, G. L., & Hoffman, R. (2014) · Experimental Hematology · doi:10.1016/j.exphem.2013.11.012 · Cited by 90 · cited 1×
“However, toxicity and resistance in RC32 cells became a significant limiting factor for the further clinical development of MDM2‐p53 inhibitors.(143,144) In 2018, the Wang group designed highly active MDM2‐targetted PROTAC MD‐224 (71) by connecting the MDM2 inhibitor MI‐1061 to a CRBN ligand.”
BackgroundJaime-Figueroa, S., Buhimschi, A. D., Toure, M., Hines, J., & Crews, C. M. (2020) · Bioorganic & Medicinal Chemistry Letters · doi:10.1016/j.bmcl.2019.126877 · Cited by 88
Cited by
An overview of PROTACs: a promising drug discovery paradigm
Liu, Z., Hu, M., Yang, Y., Du, C., Zhou, H., Liu, C., Chen, Y., Fan, L., Ma, H., Gong, Y., et al. (2022) · Molecular Biomedicine · doi:10.1186/s43556-022-00112-0 · Cited by 344
Chemistries of bifunctional PROTAC degraders
Cao, C., He, M., Wang, L., He, Y., & Rao, Y. (2022) · Chemical Society Reviews · doi:10.1039/d2cs00220e · Cited by 313
PROTACs: great opportunities for academia and industry (an update from 2020 to 2021)
He, M., Cao, C., Ni, Z., Liu, Y., Song, P., Hao, S., He, Y., Sun, X., & Rao, Y. (2022) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-022-00999-9 · Cited by 283
Characteristic roadmap of linker governs the rational design of PROTACs
Dong, Y., Ma, T., Xu, T., Feng, Z., Li, Y., Song, L., Yao, X., Ashby, C. R., & Hao, G.-F. (2024) · Acta Pharmaceutica Sinica B · doi:10.1016/j.apsb.2024.04.007 · Cited by 146
Progress and Challenges in Targeted Protein Degradation for Neurodegenerative Disease Therapy
Fang, Y., Wang, J., Zhao, M., Zheng, Q., Ren, C., Wang, Y., & Zhang, J. (2022) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.2c00844 · Cited by 100
Metadata
- Authors
- He, S., Dong, G., Cheng, J., Wu, Y., & Sheng, C.
- Venue
- Medicinal Research Reviews
- Publisher
- Wiley
- Published
- 2022-01-10
- Volume
- 42
- Issue
- 3
- Pages
- 1280-1342
- ISSN
- 0198-6325 (ISSN-L)
- 1098-1128
- OpenAlex
- W4206666355
- Cited by
- 108
- References
- 103
- FWCI
- 6.21
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.